Status:
COMPLETED
Assessment of Delphinol® Dose on Vascular Function
Lead Sponsor:
University of Memphis
Collaborating Sponsors:
Anklam-Extrakt GmbH
Conditions:
Healthy
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Maqui berry standardized extract (e.g. Delphinol®) has been used with success to modulate blood glucose and associated variables at a dosage of 450mg daily. Lower dosages have also been used with favo...
Detailed Description
Antioxidant compounds have been well-studied in relation to surrogate measures of overall health, with a particular impact on the function of blood vessels. Delphinol® is a botanical agent (an extract...
Eligibility Criteria
Inclusion
- age 18-35 years
- male or female
- body mass index (BMI) between 18-29.9 kg/m2 (not obese)
- non-smoker
- no diagnosed history of diabetes
- no diagnosed history of cardiovascular disease including any vascular disease
- no diagnosed history of neurological disease
- no consumption of alcohol or fruit within 48 hours of testing
- no consumption of caffeine-containing beverages within at least 48 hours of testing
- 12-lead ECG without significant heart rate and rhythm abnormalities and blood glucose within normal limits (as reviewed by Tara Hunter, BSN and confirmed by Dr. John Hyden, MD as needed)
- if female, not be pregnant
Exclusion
Key Trial Info
Start Date :
March 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT07196059
Start Date
March 5 2020
End Date
March 25 2020
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Nutraceutical and Dietary Supplement Research
Memphis, Tennessee, United States, 38152